streetinsider

Tandem Diabetes (TNDM) Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People ...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes ...
Business Wire

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
Business Wire

Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

SAN DIEGO-- (BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study ...
Hosted on MSN

Tandem secures FDA approval for Control-IQ+ use in pregnancy

Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...
HIT Consultant

Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements

– Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology. – This update provides users with greater flexibility and ...
HIT Consultant

FDA Clears Tandem Control-IQ+ for Type 1 Diabetes During Pregnancy: First AID System to Earn Indication

Managing type 1 diabetes during pregnancy is a high-stakes balancing act where glycemic goals are significantly tighter than for the general population. Historically, expectant mothers have had to ...
The American Journal of Managed Care

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Nasdaq

Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
Yahoo Finance

Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Benzinga.com

Tandem Diabetes Pressured As Control-IQ Trials Combined; Raymond James Downgrades TNDM

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...